









市场行情
/
股票
/
nasdaq-ikt
/

Inhibikase Therapeutics Inc

IKT

1.660USD

-0.060-3.49%

交易中（美东）报价延迟15分钟

124.18M总市值

3.53市盈率 TTM



Inhibikase Therapeutics Inc

1.660

-0.060-3.49%

概览公司财务分析

概览

公司

财务

分析

关于 Inhibikase Therapeutics Inc 公司

Inhibikase Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is focused on developing Abelson Tyrosine Kinase inhibitor therapeutics for cardiopulmonary disease. The Company’s multi-therapeutic pipeline includes IKT-001, a prodrug of imatinib mesylate, for pulmonary arterial hypertension (PAH).

Inhibikase Therapeutics Inc简介



公司代码IKT

公司名称Inhibikase Therapeutics Inc

上市日期Dec 23, 2020

CEOIwicki (Mark T)

员工数量15

证券类型Ordinary Share

年结日Dec 23

公司地址1000 N. West Street, Suite 1200

城市WILMINGTON

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编19801

电话13022953800

网址https://www.inhibikase.com/

公司代码IKT

上市日期Dec 23, 2020

CEOIwicki (Mark T)

Inhibikase Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Roberto Bellini

Independent Director

1.46M

Mr. Vincent E. (Vince) Aurentz

Independent Director

893.54K

Mr. Amit D. Munshi

Independent Chairman of the Board

431.81K

Mr. Arvind Kush

Independent Director

145.00K

Mr. David Mcintyre

Chief Financial Officer, Principal Accounting Officer

10.29K

Dr. John Adams, Ph.D.

Chief Scientific Officer

Mr. Timothy (Tim) Pigot

Chief Commercial and Strategy Officer

Mr. Dennis N. Berman

Independent Director

Dr. Roy Freeman, M.D.

Independent Director

Mr. Mike Moyer

Managing Director of LifeSci Advisors

名称

名称/职务

职务

持股

持股变动

Mr. Roberto Bellini

Independent Director

1.46M

Mr. Vincent E. (Vince) Aurentz

Independent Director

893.54K

Mr. Amit D. Munshi

Independent Chairman of the Board

431.81K

Mr. Arvind Kush

Independent Director

145.00K

Mr. David Mcintyre

Chief Financial Officer, Principal Accounting Officer

10.29K

Dr. John Adams, Ph.D.

Chief Scientific Officer

收入明细

由于公司未披露，未能获取相关数据

由于公司未披露，未能获取相关数据

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月15日周六

持股股东

股东类型

持股股东

占比

Sands Capital Ventures LLC

10.77%

Soleus Capital Management, L.P.

5.23%

Fairmount Funds Management LLC

5.07%

SP IKT Holdings LLC

4.83%

Perceptive Advisors LLC

4.48%

其他

69.62%

持股股东

占比

Sands Capital Ventures LLC

10.77%

Soleus Capital Management, L.P.

5.23%

Fairmount Funds Management LLC

5.07%

SP IKT Holdings LLC

4.83%

Perceptive Advisors LLC

4.48%

其他

69.62%

股东类型

持股股东

占比

Hedge Fund

31.76%

Investment Advisor

5.84%

Investment Advisor/Hedge Fund

4.85%

Corporation

4.83%

Private Equity

4.48%

Individual Investor

3.18%

Research Firm

0.24%

Bank and Trust

0.06%

Pension Fund

0.04%

其他

44.72%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

110

54.77M

73.50%

+878.44K

2025Q2

62.36M

83.88%

+6.72M

2025Q1

60.21M

81.40%

+7.53M

2024Q4

58.78M

83.36%

+15.59M

2024Q3

1.99M

24.34%

-203.16K

2024Q2

2.13M

28.26%

+379.22K

2024Q1

1.51M

21.65%

-625.47K

2023Q4

1.53M

25.68%

-638.36K

2023Q3

2.02M

35.52%

-749.23K

2023Q2

2.34M

41.60%

-408.30K

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

Sands Capital Ventures LLC

10.95M

14.69%

Jun 30, 2025

Soleus Capital Management, L.P.

6.33M

8.49%

Jun 30, 2025

Fairmount Funds Management LLC

6.13M

8.22%

Jun 30, 2025

SP IKT Holdings LLC

5.84M

7.84%

+5.84M

Oct 21, 2024

Perceptive Advisors LLC

5.43M

7.29%

-492.71K

-8.32%

Jun 30, 2025

Commodore Capital LP

5.40M

7.24%

+53.06K

+0.99%

Jun 30, 2025

Adar1 Capital Management LLC

5.12M

6.87%

Jun 30, 2025

The Vanguard Group, Inc.

3.22M

4.33%

+375.71K

+13.19%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

2.43M

3.25%

+2.08M

+608.12%

Jun 30, 2025

Blackstone Alternative Asset Management, L.P.

2.64M

3.54%

+567.59K

+27.41%

Jun 30, 2025

持股ETF



更新时间: 12月6日周六

机构名称

占比

iShares Micro-Cap ETF

0.02%

iShares Russell 2000 Value ETF

0.01%

ProShares Hedge Replication ETF

iShares Russell 2000 ETF

iShares Russell 2000 Growth ETF

Global X Russell 2000 ETF

Proshares Ultra Russell 2000

ProShares UltraPro Russell2000

iShares Micro-Cap ETF

占比0.02%

iShares Russell 2000 Value ETF

占比0.01%

ProShares Hedge Replication ETF

占比0%

iShares Russell 2000 ETF

占比0%

iShares Russell 2000 Growth ETF

占比0%

Global X Russell 2000 ETF

占比0%

Proshares Ultra Russell 2000

占比0%

ProShares UltraPro Russell2000

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

Jun 29, 2023

Merger

6→1

Jun 29, 2023

Merger

6→1

Jun 29, 2023

Merger

6→1

Jun 29, 2023

Merger

6→1

公告日期

类型

比率

Jun 29, 2023

Merger

6→1

Jun 29, 2023

Merger

6→1

Jun 29, 2023

Merger

6→1

Jun 29, 2023

Merger

6→1

常见问题

Inhibikase Therapeutics Inc的前五大股东是谁？



Inhibikase Therapeutics Inc 的前五大股东如下：
Sands Capital Ventures LLC持有股份：10.95M，占总股份比例：14.69%。
Soleus Capital Management, L.P.持有股份：6.33M，占总股份比例：8.49%。
Fairmount Funds Management LLC持有股份：6.13M，占总股份比例：8.22%。
SP IKT Holdings LLC持有股份：5.84M，占总股份比例：7.84%。
Perceptive Advisors LLC持有股份：5.43M，占总股份比例：7.29%。